LT2001045A - Compositions and use thereof for downmodulating the immune response to therapeutic proteins - Google Patents

Compositions and use thereof for downmodulating the immune response to therapeutic proteins

Info

Publication number
LT2001045A
LT2001045A LT2001045A LT2001045A LT2001045A LT 2001045 A LT2001045 A LT 2001045A LT 2001045 A LT2001045 A LT 2001045A LT 2001045 A LT2001045 A LT 2001045A LT 2001045 A LT2001045 A LT 2001045A
Authority
LT
Lithuania
Prior art keywords
therapeutic proteins
compositions
downmodulating
immune response
agents
Prior art date
Application number
LT2001045A
Other languages
Lithuanian (lt)
Other versions
LT4920B (en
Inventor
Jiahua Qian
Leon W. Hoyer
Mary Collins
Gary S. Gray
Original Assignee
Genetics Institute,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute,Inc. filed Critical Genetics Institute,Inc.
Publication of LT2001045A publication Critical patent/LT2001045A/en
Publication of LT4920B publication Critical patent/LT4920B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to compositions for treating a hemostatic disorder using agents which promote hemostasis and agents which inhibit a costimulatory signal in a T cell are provided. The instant compositions enable the treatment of hemostatic disorders using foreign therapeutic proteins, while downmodulating immune responses to the therapeutic proteins.
LT2001045A 1998-09-21 2001-04-20 Compositions and use thereof for downmodulating the immune response to therapeutic proteins LT4920B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21

Publications (2)

Publication Number Publication Date
LT2001045A true LT2001045A (en) 2002-01-25
LT4920B LT4920B (en) 2002-06-25

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2001045A LT4920B (en) 1998-09-21 2001-04-20 Compositions and use thereof for downmodulating the immune response to therapeutic proteins

Country Status (21)

Country Link
EP (1) EP1115423A1 (en)
JP (1) JP2002526455A (en)
KR (1) KR20010085830A (en)
CN (1) CN1331602A (en)
AU (1) AU761206B2 (en)
BR (1) BR9913991A (en)
CA (1) CA2343916A1 (en)
CZ (1) CZ20011021A3 (en)
EA (1) EA005236B1 (en)
HK (1) HK1039059A1 (en)
HU (1) HUP0103960A3 (en)
IL (1) IL142069A0 (en)
LT (1) LT4920B (en)
LV (1) LV12768B (en)
MX (1) MXPA01002898A (en)
NO (1) NO20011412L (en)
NZ (1) NZ511034A (en)
PL (1) PL346796A1 (en)
SI (1) SI20626A (en)
WO (1) WO2000016801A1 (en)
ZA (1) ZA200103156B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DE60118362T2 (en) * 2000-05-19 2007-05-24 The Center for Blood Research, Inc., Boston METHOD FOR TREATING HEMOSTATIC INTERFERENCE BY SOLUBLE P-SELECTIN
EP1636579A4 (en) * 2003-06-10 2011-10-05 Smiths Detection Inc Sensor arrangement
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (en) 1990-02-05 1994-09-02 Tm Innovation PROCESS FOR THE PREPARATION OF HUMAN FACTOR VIII AND FACTOR VIII ANALOGS.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
KR100238712B1 (en) 1991-06-27 2000-01-15 스티븐 비. 데이비스 Method for regulating the immune response using b7 binding molecules and il4-binding molecules
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996005860A1 (en) * 1994-08-19 1996-02-29 Novo Nordisk A/S A method of treating a patient with a biologically active compound
JPH10507758A (en) * 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド Gene therapy with simultaneous administration of adenovirus and immunosuppressive drugs
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
PT892643E (en) * 1996-03-20 2002-09-30 Univ Emory METHODS FOR INHIBITING AN IMMUNITY RESPONSE BLOCKING THE GP39 / CD40 AND CTLA4 / CD28 / B7 CIRCUITS AND USES FOR THE EFFECT
ATE356634T1 (en) * 1997-01-10 2007-04-15 Biogen Idec Inc METHOD FOR THERAPEUTIC ADMINISTRATION OF ANTI-CD40L AGENTS
TR199903141T2 (en) * 1997-06-20 2000-09-21 Biogen, Inc. CD154 blockade therapy for therapeutic protein blocker syndrome.
US8099877B2 (en) 2009-11-06 2012-01-24 Hexagon Metrology Ab Enhanced position detection for a CMM

Also Published As

Publication number Publication date
CA2343916A1 (en) 2000-03-30
AU761206B2 (en) 2003-05-29
LT4920B (en) 2002-06-25
MXPA01002898A (en) 2002-06-04
HK1039059A1 (en) 2002-04-12
LV12768B (en) 2002-06-20
EP1115423A1 (en) 2001-07-18
HUP0103960A2 (en) 2002-02-28
BR9913991A (en) 2001-07-03
KR20010085830A (en) 2001-09-07
IL142069A0 (en) 2002-03-10
WO2000016801A1 (en) 2000-03-30
PL346796A1 (en) 2002-02-25
CN1331602A (en) 2002-01-16
HUP0103960A3 (en) 2003-09-29
SI20626A (en) 2002-02-28
ZA200103156B (en) 2002-07-18
JP2002526455A (en) 2002-08-20
NO20011412D0 (en) 2001-03-20
NO20011412L (en) 2001-05-16
EA005236B1 (en) 2004-12-30
AU6057899A (en) 2000-04-10
NZ511034A (en) 2004-03-26
WO2000016801A9 (en) 2000-10-26
CZ20011021A3 (en) 2001-10-17
EA200100385A1 (en) 2001-10-22
LV12768A (en) 2001-12-20

Similar Documents

Publication Publication Date Title
IL159422A0 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
ATE296634T1 (en) (S,S)-REBOXETINE FOR THE TREATMENT OF FIBROMYALGIA AND OTHER SOMATOFORM DISORDERS
TR199901172T2 (en) Newly substituted pyrazole derivatives.
WO2002060955A3 (en) Modified antibodies and methods of use
ATE257390T1 (en) USE OF A BPI PROTEIN PRODUCT AS AN ANTITHRBOTIC AGENT
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
TR199801390T2 (en) Anticoagulants to be used in the treatment of thrombosis
CA2180950A1 (en) Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
TR200002773T2 (en) Smilagen and anzurogenin-D and their use for the treatment of Alzheimer's.
MX9700538A (en) Use of droloxifene for the treatment of cardiovascular diseases.
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
ATA76995A (en) STABLE PREPARATION FOR TREATING BLOOD COIST DISORDERS
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
PL329940A1 (en) Compositions for once-a-day administration for use in treating diseases involving mediator effect of cyclooxygenase-2
WO1997040072A3 (en) Adam proteins and uses thereof
ATE234111T1 (en) THERAPEUTIC USES OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BLEEDING CAUSED BY TRAUMA
FI972703A (en) Recombinant IL-5 antagonists useful in the treatment of IL-5-related diseases
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
DE69711078D1 (en) TOPICAL USE OF KAPPA OPIOID RECEPTORAGONISTS FOR THE TREATMENT OF EYE PAIN
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
LT2001045A (en) Compositions and use thereof for downmodulating the immune response to therapeutic proteins
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
TR200200278T2 (en) Calcilitic compositions
PT888114E (en) USING (+) - ALPHA- (2,3-DIMETOXYPHENYL) -1- [2- (4-FLUOROPHENYL) ETHYL] -4-PIPERIDINOMETHANOL IN THE TREATMENT OF DEPRESSIVE DISEASES AND BIPOLAR DISEASES
HU9600934D0 (en) Oligopeptides derived from c-reactive protein fragments

Legal Events

Date Code Title Description
PD9A Change of patent owner

Owner name: AMERICAN RED CROSS, US

Free format text: FORMEROWNER: GENETICS INSTITUTE, LLC, US

Effective date: 20031223

MM9A Lapsed patents

Effective date: 20050921